BioPivot Review: Following the Care Handoffs From Intake to Delivery

With BioPivot, the central care-delivery question is not simply which medication appears on the website. It is who takes responsibility at each handoff: the platform collecting your information, the clinician deciding whether to prescribe, the pharmacy preparing medication and the team responding afterward. BioPivot names clinical and pharmacy contacts, publishes treatment prices and describes portal messaging. Those are useful starting points, but they do not establish every detail of the experience a patient would receive.

This review follows that pathway using public documentation consulted October 19, 2026. BioPivot presents itself as a technology platform facilitating access to compounded semaglutide and tirzepatide, including programs labeled microdosing. Its documentation also contains consequential differences: a free-review advertisement versus a potential $59 consultation charge, and monthly pricing alongside a three-month membership policy. The practical issue is whether a prospective patient can obtain a clear, written account of the clinical, pharmacy and financial arrangements before enrollment.

At a glance

Platform, not clinical practice: BioPivot, LLC says it connects users to independent providers and pharmacies; it does not itself practice medicine, prepare medication or dispense prescriptions.
Sources: [10]
Named care partners: The website identifies Elite Care Health for clinical care and Rx Ave Health for pharmacy and prescription fulfillment.
Sources: [12]
Published treatment prices: Compounded semaglutide Starter is listed at $185 monthly or $400 quarterly; compounded tirzepatide Starter is $242 monthly or $590 quarterly. Other tiers have different prices.
Sources: [11] [6]
Review-charge conflict: The homepage advertises a free first review and $0 if not approved, while the cancellation policy retains a $59 consultation fee when a provider determines someone is not a candidate.
Sources: [12] [9]
Delivery remedies have deadlines: BioPivot requests reports of damaged or incorrect deliveries within seven days, with photos, and tracking-confirmed lost shipments within 14 days of the expected delivery date.
Sources: [9]

Start by separating the platform from the care team

BioPivot, LLC owns and operates the website, according to its terms. Those terms describe a limited role: connecting patients with independent third parties without directing or controlling their professional judgment. The homepage identifies Elite Care Health as the clinical-care organization and Rx Ave Health as the pharmacy and fulfillment contact. This distinction matters because an account problem, a prescribing question and a medication-delivery problem may require different recipients, even when purchased through one interface.

BioPivot describes access to independent, U.S. board-certified clinical providers and state-licensed compounding pharmacies. These are provider statements, not credentials independently verified in this review. Its cancellation policy says all medications dispensed through the service are customized preparations from licensed 503A compounding pharmacies. However, the consulted pages do not establish which specific preparing pharmacy would handle an individual prescription. Rx Ave Health’s named fulfillment role should not be treated as proof that it compounds every order.

Before paying, ask who will prescribe, which pharmacy will prepare and dispense the medication, and who handles questions after delivery. Our explanation of the clinician-platform distinction provides context for those separate responsibilities. BioPivot’s terms also mention Pura Labs LLC within a HIPAA clause without explaining its relationship to BioPivot. That inconsistency warrants clarification about the entities handling information, but does not establish a legal conclusion about their relationship.

Sources: [10] [12] [9]

The intake is a review process, not a prescription promise

The advertised starting point is a brief online intake reviewed by the care team before a conversation with a physician. Elsewhere, BioPivot uses the broader term licensed medical provider and says the reviewer may request additional information, laboratory work or a consultation before deciding. That leaves the exact consultation format unresolved. Completing the form or selecting a program does not guarantee treatment, and the website’s BMI calculator is described as a starting point rather than an eligibility decision.

The terms require users to be at least 18, or the local age of majority if higher. During a provider consultation, the patient must physically be in the same state as the shipping address on the account. BioPivot says telehealth may be available in all 50 states where clinically appropriate and legally permitted; this is conditional availability, not confirmation that every treatment is accessible everywhere. Confirm the intended consultation location and shipping state before starting.

BioPivot’s treatment page excludes patients with a personal or family history of medullary thyroid carcinoma or MEN 2, and patients who are pregnant or breastfeeding. It says a full medical history is reviewed before authorization. These are documented provider restrictions, not a complete individual screening determination. For practical preparation, questions for a first consultation can help organize medication history, existing records and questions without assuming a particular treatment will be approved.

Sources: [12] [10] [11]

Match the quoted price to the actual treatment

BioPivot publishes monthly and quarterly alternatives for compounded semaglutide and tirzepatide. The table preserves those alternatives rather than treating quarterly payment as mandatory. Starter, Continuation and Maintenance are commercial plan labels; their duration, supply quantity and transition rules are not established by the price list alone. The consulted text also does not expressly identify the administration route or presentation of these GLP-1 products, so an ingredient name is not enough to identify exactly what would arrive.

The homepage separately advertises plans from $149 per month, confirmed after provider review, without identifying the product or conditions behind that minimum. Treatment pages advertise 20% off a first order with BIOPIVOT20; this is an introductory offer, not a documented ongoing discount. The terms describe a bundled price covering pharmacy medication, medical-group services and platform access. Nevertheless, laboratory charges, administration supplies, possible extra consultations and any additional shipping costs need explicit confirmation rather than an assumption that every related expense is included.

Published compounded-medication prices; quarterly collection terms and GLP-1 route/presentation require confirmation.
Documented offering	Monthly option	Quarterly option
Semaglutide Starter	$185	$400
Semaglutide Continuation / Maintenance	$218 / $225	$490 / $518
Tirzepatide Starter	$242	$590
Tirzepatide Continuation / Maintenance	$315 / $350	$780 / $900
Microdosing: semaglutide / tirzepatide	$168 / $220	$370 / $528

Sources: [11] [6] [8] [12] [10]

Resolve the payment rules before clinical review begins

The first financial uncertainty concerns an unsuccessful application. The homepage calls the first review free and says patients pay $0 if not approved. The cancellation policy instead says that when a provider reviews an intake and determines the applicant is not a candidate, the membership payment is refunded minus a $59 doctor consultation fee. These statements cannot both describe the same charge without further explanation. A written answer should identify which rule governs the specific checkout offer.

The ongoing arrangement also needs clarification. The cancellation policy describes a three-month telehealth membership including medical review, provider support, messaging and fulfillment if approved. Meanwhile, recurring-monthly-order terms authorize an immediate charge and subsequent charges every 30 days until cancellation, with electronic notice five to seven days before a scheduled transaction. Thirty days is not necessarily a calendar month. The documentation does not explain how those recurring charges fit the quarterly options or whether quarterly charges are collected upfront.

BioPivot publishes baseline and follow-up laboratory services when a provider considers them appropriate. Its Comprehensive Panel is listed at $228.30 and includes blood counts, metabolic testing, A1c, thyroid markers and other listed tests; the pages do not establish whether that charge is included in a treatment program. A Tasso home capillary-collection kit is labeled coming soon without a price. Insurance acceptance, insurer billing, out-of-network reimbursement and HSA/FSA use are not documented in the consulted material.

Sources: [12] [9] [10]

The pharmacy handoff needs product-level answers

BioPivot’s terms require people purchasing a prescription-containing service to accept fulfillment through the platform’s pharmacies, describing this as a waiver of choosing another pharmacy. That is a meaningful channel restriction for someone hoping to use a local pharmacy. Before purchase, obtain the proposed pharmacy’s identity, the precise formulation, route, presentation and instructions. The prescription-to-pharmacy handoff is where those specifics should become clear, rather than remaining implied by the program name.

BioPivot acknowledges that compounded medications are not FDA approved and are not evaluated by FDA for safety, effectiveness or quality. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not demonstrate clinical inequivalence, but neither the platform’s credentials language nor pharmacy status amounts to FDA approval of the preparation. The clinician should explain the product-specific rationale rather than relying only on general ingredient familiarity.

The microdosing offerings do not establish their own clinical outcomes merely by being listed. Trials of other products, routes or study regimens cannot validate BioPivot’s preparations or predict an individual result. FDA has also received reports of measuring or administration errors with compounded medication, including some associated with hospitalization. Clarifying instructions with the prescriber or pharmacist is therefore important. BioPivot’s terms additionally warn that prescription products will not be dispensed in child-resistant containers, a material packaging detail to resolve before delivery.

Sources: [10] [12] [9] [8] [1] [3] [4]

Keep approval, shipping and arrival on separate clocks

BioPivot says most applicants hear back within 48 hours. That is an application-response statement, not a promise of prescribing, dispatch or arrival within that window. The program describes medication prepared by partner compounding pharmacies and shipped on a structured cadence, with temperature-controlled, unmarked packaging delivered discreetly. However, the consulted pages do not specify preparation times, carriers, arrival estimates or exact shipment frequency. A quarterly price therefore should not be read as proof of one three-month shipment.

The delivery policy provides concrete reporting windows. For damaged orders or the wrong medication or dosage, contact info@biopivot.co within seven days of delivery and include photos of the packaging and product; BioPivot says it will coordinate a no-cost replacement. If tracking confirms a shipment was lost and not delivered, report it within 14 days of the expected delivery date for reshipment at no additional charge. These remedies are more specific than the general shipping description.

Temperature concerns deserve separate attention from ordinary package damage. FDA explicitly advises not using an injectable GLP-1 product that arrives warm or inadequately refrigerated, and contacting the provider or dispensing pharmacy to resolve the concern. Our guide to warm injectable deliveries explains that distinction. This advice does not establish that BioPivot’s unspecified GLP-1 presentation is injectable; it applies if an injectable product is prescribed and delivered. Request storage and delivery instructions for the actual preparation.

Sources: [11] [12] [9] [1]

Follow-up is described, but its operating details remain open

BioPivot advertises direct physician messaging through a secure patient portal between scheduled check-ins, plus structured reviews intended to adjust the protocol and wellness plan to the patient’s response. It does not state the exact review frequency or clinical-message response standard. NIDDK describes follow-up as concerning tolerance and response, not merely continued payment. Ask when the first review occurs, who reads messages, and what route is available when a concern cannot wait for the next scheduled check-in.

The contact page lists info@biopivot.co and 520-210-4673, with clinical hours Monday through Friday, 9 a.m. to 5 p.m.; that block does not specify a time zone. A contact-form statement promises a team response within 24 hours, distinct from the homepage’s 48-hour application-response claim. Neither statement documents round-the-clock clinical availability. The clinical contact is mayur@elite-care.health or 810-348-3003; pharmacy questions are directed to info@rxave.health or (833) 360-4276. Confirm which channel handles each type of concern.

Information handling is another handoff to understand. BioPivot’s general privacy statement says it does not sell, rent or trade personal information. Its California notice says certain advertising disclosures may count as a sale or sharing under that state’s law, and specifies that the California notice takes priority for those consumers. These statements should be read together rather than reduced to a blanket privacy assurance. They do not, by themselves, establish that clinical records are sold.

Sources: [11] [7] [12] [5] [2]

Cancellation changes with the stage of care

The policy permits cancellation through Account > Subscription > Cancel Membership, by email with the account name and email address, or by phone during business hours. It says requests are processed within one business day and remaining benefits continue through the three-month membership period. Separately, the terms require turning off auto-refill at least 48 hours before the monthly processing date. Until BioPivot reconciles these provisions, cancellation access should not be mistaken for assurance that an imminent renewal will stop.

Before provider review begins, the policy allows a full refund of membership or intake fees paid. After a prescription is issued but before shipment, it describes a partial membership refund minus $59, yet warns that cancellation cannot be guaranteed once the order reaches the pharmacy. After shipment, compounded-medication sales are final except for the stated pharmacy-error or damaged/incorrect-delivery exceptions. Approved refunds are processed within five to ten business days; a bank may require another three to five business days to show the credit.

Sources: [9] [10]

Questions & answers

Does BioPivot itself provide medical care?

Its terms say no: BioPivot is the technology platform, not the medical practice or dispensing pharmacy. The homepage names Elite Care Health for clinical care and Rx Ave Health for pharmacy and fulfillment. Ask for the individual prescriber and dispensing pharmacy before treatment, since these organizational contacts do not identify everyone who would handle your case.

Sources: [10] [12]

What will I pay if BioPivot does not approve treatment?

The public pages conflict. The homepage advertises $0 if not approved, but the cancellation policy says a provider’s determination that someone is not a candidate leads to a refund minus a $59 consultation fee. Obtain written confirmation for your offer before submitting payment or allowing clinical review to begin.

Sources: [12] [9]

Does the quarterly price mean I must prepay for three months?

That is not established by the consulted documentation. BioPivot publishes quarterly alternatives, describes a three-month membership and separately authorizes recurring monthly charges every 30 days. Ask for the amount collected today, subsequent charge dates, shipment schedule and any remaining obligation after cancellation. Package duration alone does not establish supply quantity or a minimum commitment.

Sources: [11] [6] [9] [10]

Can I send a BioPivot prescription to my usual pharmacy?

The terms condition purchase of a prescription-containing service on accepting the platform’s pharmacy channel and waiving pharmacy choice. Do not assume the service includes transfer to a preferred local pharmacy. Ask about that restriction before buying, and request the actual preparing and dispensing pharmacy’s details rather than relying solely on the named fulfillment contact.

Sources: [10] [12]

Is the advertised 48-hour response a delivery promise?

No. BioPivot says most applicants hear back within 48 hours; it does not describe that as a medication-arrival deadline. Additional information, laboratory work or consultation may be requested before a prescribing decision. The public text does not establish pharmacy preparation, dispatch or delivery times, so ask for those estimates separately after the care plan is clear.

Sources: [12] [11]

What should I confirm about ongoing clinical support?

Ask how often scheduled check-ins occur, who responds through the portal, the expected response time and the process outside posted hours. BioPivot advertises direct physician messaging and structured check-ins, but does not specify their frequency. Its contact page lists weekday clinical hours without a time zone, and a general contact-form response promise is not an emergency-care arrangement.

Sources: [11] [7]

Our assessment

BioPivot documents more of its care pathway than a price-only storefront: named organizational contacts, conditional clinical review, bundled-service language, portal messaging and specific delivery-remedy deadlines. Those details give prospective patients concrete points to verify. The unresolved issues, however, sit at consequential handoffs: the exact prescription and pharmacy, consultation format, shipment timing, follow-up frequency and the relationship between monthly charges and a three-month membership. The free-review versus $59 discrepancy is especially important because it affects people who never receive treatment. BioPivot is best evaluated through a written, patient-specific explanation of these arrangements before payment—not through its starting price, national-availability language or ingredient names alone. Its public documentation supports identifying it as a platform facilitating compounded GLP-1 care, but does not establish independently verified credentials, provider-specific outcomes or a fully predictable delivery experience.

Visit BioPivot’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

FOLLOW THE EVIDENCE

Research behind treatment claims

Use these studies to assess the type of outcome a treatment claim describes. They did not test this provider or establish results for its products.

SURMOUNT-5: What a Direct Weight-Loss Comparison Can—and Cannot—Tell You About Ongoing Care
Tirzepatide produced greater average weight and waist reductions than semaglutide over 72 weeks. Understanding the trial’s design matters just as much as understanding the difference.
After the Weight Loss: What SURMOUNT-4 Means for Continuity of Care
Randomized tirzepatide withdrawal separates maintaining a treatment effect from finishing a course. Reading its two baselines—and newer maintenance-dose research—shows what the evidence can and cannot tell patients changing care.

Explore the science library →

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

BioPivot Review: Following the Care Handoffs From Intake to Delivery

At a glance

01Start by separating the platform from the care team

02The intake is a review process, not a prescription promise

03Match the quoted price to the actual treatment

04Resolve the payment rules before clinical review begins

05The pharmacy handoff needs product-level answers

06Keep approval, shipping and arrival on separate clocks

07Follow-up is described, but its operating details remain open

08Cancellation changes with the stage of care